1. Home
  2. ACCO vs CAPR Comparison

ACCO vs CAPR Comparison

Compare ACCO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACCO
  • CAPR
  • Stock Information
  • Founded
  • ACCO 1893
  • CAPR 2005
  • Country
  • ACCO United States
  • CAPR United States
  • Employees
  • ACCO N/A
  • CAPR N/A
  • Industry
  • ACCO Publishing
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ACCO Consumer Discretionary
  • CAPR Health Care
  • Exchange
  • ACCO Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • ACCO 353.3M
  • CAPR 324.6M
  • IPO Year
  • ACCO N/A
  • CAPR N/A
  • Fundamental
  • Price
  • ACCO $4.00
  • CAPR $6.28
  • Analyst Decision
  • ACCO Buy
  • CAPR Strong Buy
  • Analyst Count
  • ACCO 1
  • CAPR 8
  • Target Price
  • ACCO $6.00
  • CAPR $24.75
  • AVG Volume (30 Days)
  • ACCO 530.2K
  • CAPR 1.4M
  • Earning Date
  • ACCO 07-31-2025
  • CAPR 08-11-2025
  • Dividend Yield
  • ACCO 7.46%
  • CAPR N/A
  • EPS Growth
  • ACCO N/A
  • CAPR N/A
  • EPS
  • ACCO 0.49
  • CAPR N/A
  • Revenue
  • ACCO $1,581,200,000.00
  • CAPR $13,392,150.00
  • Revenue This Year
  • ACCO N/A
  • CAPR N/A
  • Revenue Next Year
  • ACCO $2.11
  • CAPR $6,061.53
  • P/E Ratio
  • ACCO $8.21
  • CAPR N/A
  • Revenue Growth
  • ACCO N/A
  • CAPR N/A
  • 52 Week Low
  • ACCO $3.32
  • CAPR $3.98
  • 52 Week High
  • ACCO $6.44
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • ACCO 59.22
  • CAPR 36.33
  • Support Level
  • ACCO $3.90
  • CAPR $6.17
  • Resistance Level
  • ACCO $4.01
  • CAPR $7.30
  • Average True Range (ATR)
  • ACCO 0.10
  • CAPR 0.43
  • MACD
  • ACCO 0.01
  • CAPR -0.11
  • Stochastic Oscillator
  • ACCO 79.91
  • CAPR 4.53

About ACCO Acco Brands Corporation

ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: